BRPI0915592A2 - composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii - Google Patents

composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii Download PDF

Info

Publication number
BRPI0915592A2
BRPI0915592A2 BRPI0915592A BRPI0915592A BRPI0915592A2 BR PI0915592 A2 BRPI0915592 A2 BR PI0915592A2 BR PI0915592 A BRPI0915592 A BR PI0915592A BR PI0915592 A BRPI0915592 A BR PI0915592A BR PI0915592 A2 BRPI0915592 A2 BR PI0915592A2
Authority
BR
Brazil
Prior art keywords
compound
treatment
type
diabetes mellitus
prophylaxis
Prior art date
Application number
BRPI0915592A
Other languages
English (en)
Inventor
Ma Chun
Wright Tilley Jefferson
Richard Guertin Kevin
Kim Kyungjin
Qi Lida
Gillespie Paul
Saba Karnachi Prabha
Zhang Qiang
David Erickson Shawn
Lynn Pietranico-Cole Sherrie
William Mccomas Warren
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0915592A2 publication Critical patent/BRPI0915592A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii proporcionam-se neste contexto compostos da fórmula (i) :bem como os seus sais farmaceuticamente aceitáveis, em que os substituintes são tais como aqueles expostos no relatório. estes compostos, e as composições farmacêuticas que os contêm, são de utilidade para o tratamento metabólico de enfermidades e distúrbios tais como, por exemplo, diabetes mellitus do tipo ii.
BRPI0915592A 2008-05-19 2009-05-11 composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii BRPI0915592A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5422708P 2008-05-19 2008-05-19
PCT/EP2009/055644 WO2009141238A1 (en) 2008-05-19 2009-05-11 Gpr119 receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0915592A2 true BRPI0915592A2 (pt) 2019-08-27

Family

ID=40834412

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915592A BRPI0915592A2 (pt) 2008-05-19 2009-05-11 composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii

Country Status (11)

Country Link
US (1) US8188098B2 (pt)
EP (1) EP2283019A1 (pt)
JP (1) JP2011520935A (pt)
KR (1) KR20110008242A (pt)
CN (1) CN102036991A (pt)
AU (1) AU2009249793A1 (pt)
BR (1) BRPI0915592A2 (pt)
CA (1) CA2724011A1 (pt)
IL (1) IL208919A0 (pt)
MX (1) MX2010012292A (pt)
WO (1) WO2009141238A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
EP2399914A4 (en) 2009-02-18 2012-08-29 Takeda Pharmaceutical FUSED HETEROCYCLIC CORE COMPOUND
AR077214A1 (es) * 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
AU2010264720A1 (en) * 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
JP5909185B2 (ja) 2009-10-01 2016-04-26 シマベイ セラピューティクス， インコーポレーテッド 置換テトラゾール−１−イルフェノキシメチルチアゾール−２−イルピペリジニルピリミジン塩
WO2011062889A1 (en) * 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
EA201291460A1 (ru) 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR20120011357A (ko) * 2010-07-23 2012-02-08 현대약품 주식회사 치환된 피리디논 유도체 및 이의 제조방법
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
JP2013253019A (ja) * 2010-09-28 2013-12-19 Kowa Co 新規なピペリジン誘導体及びこれを含有する医薬
EP2625177B1 (en) 2010-10-08 2015-07-29 Cadila Healthcare Limited Novel gpr 119 agonists
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
CN102731492B (zh) * 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US9487495B2 (en) 2012-01-06 2016-11-08 The Scripts Research Institute Carbamate compounds and of making and using same
AU2013214353A1 (en) 2012-02-03 2014-08-21 Basf Se Fungicidal pyrimidine compounds
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN102786525B (zh) * 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN103113375B (zh) * 2013-02-21 2017-09-15 南京勇山生物科技有限公司 一类吡唑并[3,4‑d]嘧啶类化合物及其制备方法
PL3417851T3 (pl) 2013-09-09 2020-12-14 Peloton Therapeutics, Inc. Etery arylowe i ich zastosowanie
US9884843B2 (en) * 2013-12-16 2018-02-06 Peloton Therapeutics, Inc. Cyclic sulfone and sulfoximine analogs and uses thereof
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
EP3212624A1 (en) * 2014-10-30 2017-09-06 Sandoz AG Synthesis of substituted 1h-pyrazolo[3,4-d]pyrimidines
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR20210010475A (ko) 2018-05-15 2021-01-27 룬드벡 라 졸라 리서치 센터 인코포레이티드 Magl 저해제
CN108503632B (zh) * 2018-06-26 2020-07-28 北京圣永制药有限公司 一种吲哚类衍生物及其在糖尿病中的应用
JP2023504623A (ja) * 2019-12-04 2023-02-06 アーカス バイオサイエンシーズ，インコーポレーテッド Ｈｉｆ－２アルファの阻害剤
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
IL297470A (en) 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN117070576A (zh) * 2023-10-16 2023-11-17 吉林凯莱英制药有限公司 制备肼类化合物的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
RS20060018A (sr) * 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
WO2005019222A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists
GB0326168D0 (en) 2003-11-10 2003-12-17 Arrow Therapeutics Ltd Chemical compounds
CA2547248A1 (en) 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
DE102005047600A1 (de) * 2005-10-05 2007-04-12 Robert Bosch Gmbh Handwerkzeugmaschine mit einer Welle und mit einem auf der Welle gelagerten Hubantriebslager
US8314234B2 (en) 2006-09-25 2012-11-20 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
ES2388315T3 (es) * 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists

Also Published As

Publication number Publication date
AU2009249793A1 (en) 2009-11-26
US20090286812A1 (en) 2009-11-19
EP2283019A1 (en) 2011-02-16
CN102036991A (zh) 2011-04-27
KR20110008242A (ko) 2011-01-26
JP2011520935A (ja) 2011-07-21
MX2010012292A (es) 2010-12-17
IL208919A0 (en) 2011-01-31
CA2724011A1 (en) 2009-11-26
WO2009141238A1 (en) 2009-11-26
US8188098B2 (en) 2012-05-29

Similar Documents

Publication Publication Date Title
BRPI0915592A2 (pt) composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CL2008002052A1 (es) Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia
BRPI0817060A2 (pt) composto, processo para a preparação destes compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são modulados por agonistas receptores de hormônio da tireóide e usos destes compostos
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
UY30759A1 (es) Compuestos quimicos
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
CL2010001496A1 (es) Compuestos derivados de (piridin-o pirimidin-)piperidina, agonistas de gpr119; composicion farmaceutica; y su uso para el tratamiento de la diabetes de tipo i, diabetes de tipo ii y enfermedades relacionadas tales como sindrome metabolico, dislipidemia y resistencia a la insulina.
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0606675A2 (pt) agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
UY31141A1 (es) Compuestos de piperidina y sus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2539 DE 03-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]